Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up
Cytomegalovirus (<scp>CMV</scp>) seroprevalence in <scp>J</scp>apanese blood donors and high detection frequency of <scp>CMV DNA</scp> in elderly donors
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Prevalence of Cytomegalovirus Antibodies in Brazilian and Japanese Populations in the North‐East of Brazil
Retrospective multicenter study on the development of peripheral lymphocytosis following second‐line dasatinib therapy for chronic myeloid leukemia
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase